Eli Lilly & Co 532457108 US5324571083 BBG000BNBDC2 05/06/2024 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 9200 0 FOR 9200 FOR Merus NV NL0011606264 BBG00B8LXMS5 05/07/2024 Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES 72924 0 FOR 72924 FOR Danaher Corp 235851102 US2358511028 BBG000BH3JF8 05/07/2024 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 108700 0 FOR 108700 FOR Corbus Pharmaceuticals Holdings Inc 21833P301 US21833P3010 BBG0078PJKQ7 05/16/2024 Approval, on an advisory basis, of the executive compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 72612 0 FOR 72612 FOR Alnylam Pharmaceuticals Inc 02043Q107 US02043Q1076 BBG000BFGNJ5 05/16/2024 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES 200 0 FOR 200 FOR Thermo Fisher Scientific Inc 883556102 US8835561023 BBG000BVDLH9 05/22/2024 An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 18400 0 FOR 18400 FOR Day One Biopharmaceuticals Inc 23954D109 US23954D1090 BBG00V1KSN04 05/23/2024 Approval, on a non-binding advisory basis, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 99550 0 FOR 99550 FOR Day One Biopharmaceuticals Inc 23954D109 US23954D1090 BBG00V1KSN04 05/23/2024 Selection, on a non-binding advisory basis, of whether future advisory votes on the compensation of our named executive officers should be every one, two or three years. SECTION 14A SAY-ON-PAY VOTES 99550 0 1 Year 99550 FOR Denali Therapeutics Inc 24823R105 US24823R1059 BBG008P7F869 05/31/2024 Advisory vote on executive compensation SECTION 14A SAY-ON-PAY VOTES 209613 0 FOR 209613 FOR Kiniksa Pharmaceuticals International Plc GB00BRXB0C07 BBG00KT2KFX7 06/05/2024 To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. SECTION 14A SAY-ON-PAY VOTES 400441 0 FOR 400441 FOR Apellis Pharmaceuticals Inc 03753U106 US03753U1060 BBG007KGRPY4 06/05/2024 Approval of an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 287277 0 FOR 287277 FOR Bridgebio Pharma Inc 10806X102 US10806X1028 BBG00P9KDZK6 06/21/2024 To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 536794 0 FOR 536794 FOR